Rankings/Insilico Medicine
Insilico Medicine logo

Insilico Medicine

IntegratedApplied AIPublic · 3696.HKUpdated November 15, 2026

The only AI-designed drug in Phase II clinical trials — a genuine milestone in AI-driven drug discovery.

Founded
2014
CEO
Alex Zhavoronkov
HQ
Cambridge, Hong Kong
Stage
Public
Revenue
$50M–$100M
Employees
201-500
Flag a data issue
Healthcare ToolsHealthcare
48.2Bluescore
Momentum67.2
Market MapDeep Tech
Rank change (7d)▼ 43

Executive Summary

Updated Nov 15, 2026

What they do

  • Generative AI drug discovery covering target identification, molecule design and clinical prediction
  • Licenses its Pharma.AI software suite, including PandaOmics, Chemistry42 and inClinico, to pharma R&D teams
  • Develops its own pipeline, led by rentosertib, a TNIK inhibitor for IPF now in Phase III

Why it matters

  • Rentosertib is the first generative-AI-discovered drug to reach a Phase III trial
  • About US$7.3B in disclosed deal value signed in 2026, including SK Biopharmaceuticals and Takeda
  • H1 2026 revenue was US$106.3M, up 287%, and the company turned a net profit

Best fit

  • Large pharma looking for AI co-discovery deals with milestone-based economics
  • Biotech R&D teams that want licensed generative chemistry and target-discovery software
  • Companies working in fibrosis, oncology, CNS or immunology that want faster candidate nomination

Watch-outs

  • Revenue depends on upfront and milestone payments that can swing from period to period
  • Rentosertib's Phase III result is pending, so the clinical validation is not yet final
  • Much of its R&D runs in China, which may draw geopolitical and data-governance scrutiny

Products & Offerings

Pharma.AI

End-to-end generative AI drug discovery platform covering biology, chemistry and clinical development, offered by license and through partnerships.

PlatformEnterpriseCore Platform

Chemistry42

Generative chemistry engine that designs and optimizes novel small molecules with target properties.

Developer ToolEnterpriseFlagship

PandaOmics

AI target discovery engine that analyzes multi-omics data and literature to rank novel therapeutic targets.

DataEnterpriseLive

inClinico

Predictive model that estimates the likelihood that clinical trials will succeed, for portfolio and trial-design decisions.

ModelEnterpriseLive

Rentosertib (ISM001-055)

Oral TNIK inhibitor for idiopathic pulmonary fibrosis, discovered with AI and now in the Phase III GENESIS-IPF-3 trial.

EnterpriseEnterpriseHigh Growth

Recent Releases

Latest News

Analyst VerdictShortlist

Updated Nov 15, 2026

Insilico is the most clinically advanced generative-AI drug discovery company: it has a Phase III asset, several big-pharma deals in 2026 and now reports a profit. Pharma and biotech R&D leaders looking for AI co-discovery partners or generative chemistry software should include it in their evaluations. Before signing, check how IP and milestones are structured, and assess China data-residency and supply-chain exposure.

Signal Provenance

Latest observation date and source for each signal category

Signal CategoryLast UpdatedSource
Funding Signals
Last funding round, Funding stage
Nov 5, 2026Cited web research
Hiring Velocity
Headcount, Headcount growth
Nov 15, 2026Research agents (estimate)
Technical Output
Research papers, GitHub activity
Nov 15, 2026Hugging Face Hub + news feed + research agents
News Sentiment
News mentions, News sentiment
Nov 15, 2026Verified news feed
Partnership Signals
Enterprise partnerships, Distribution partners
Oct 31, 2026Research agents (estimate)
Revenue Indicators
ARR estimate, Revenue growth
Nov 15, 2026SEC filings
Leadership Signals
CEO tenure, Founder-led
Nov 15, 2026Research agents (estimate)
Competitive Position
Category rank, Market share
Nov 15, 2026Research agents (estimate)

Why this Bluescore?

6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology

Insilico Medicine's Bluescore of 48.2 rests most on Data & Model Moat (8.6, top 2%) and Talent & Research (5.6, 67th percentile). Its weakest area is Customer Adoption (4.0, 9th percentile).

In plain English

Insilico Medicine's Bluescore of 48.2 is held up mainly by Data & Model Moat, where its score of 8.6 of 10 sits at the 98th percentile and adds 16.3 of 19 possible points. The biggest drags are Product Depth, which scores 3.1 of 10 (18th percentile) and adds only 6.6 of 21 points, and Investment Momentum, which scores 2.1 of 10 (11th percentile). Product Depth would move the score most, since it carries a 21% weight and still has 14.4 points left to gain.

Written by AI from the scores below and checked against them; updated nightly.

D1 · Business Model & Revenue (21%)
4.4
+9.2 of 21 pts · 45th pct
D2 · Product Depth (21%)
3.1
+6.6 of 21 pts · 18th pct
D3 · Data & Model Moat (19%)
8.6
+16.3 of 19 pts · Top 2%
D4 · Talent & Research (16%)
5.6
+8.9 of 16 pts · 67th pct
D5 · Customer Adoption (13%)
4.0
+5.1 of 13 pts · 9th pct
D6 · Investment Momentum (10%)
2.1
+2.1 of 10 pts · 11th pct

Traction Signals

Last Round

Public

Risks

Updated Nov 15, 2026

A Phase III failure for rentosertib would undercut the AI validation story
High
US-China tensions could affect partnerships that depend on China-based R&D operations
Medium
Profitability depends on deal upfronts and may not hold every year
Medium
Building its own pipeline may create IP conflicts with partner programs
Medium
Competition from Isomorphic Labs, Recursion and in-house pharma AI teams is growing
Low
Feedback